NCT00374998View on ClinicalTrials.gov

Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 30, 2006

Study Completion Date

January 31, 2007

Conditions
Malaria, FalciparumMalaria
Interventions
BIOLOGICAL

FP9-PP (FP9 polyprotein)

BIOLOGICAL

MVA-PP (Modified Virus Ankara polyprotein)

Trial Locations (1)

OX3 7LJ

Centre for Clinical Vaccinology & Tropical Medicine, University of Oxford, Oxford

All Listed Sponsors
collaborator

University of Oxford

OTHER

collaborator

Wellcome Trust

OTHER

lead

European Vaccine Initiative

OTHER

NCT00374998 - Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP | Biotech Hunter | Biotech Hunter